90. Retinitis pigmentosa Clinical trials / Disease details


Clinical trials : 130 Drugs : 180 - (DrugBank : 41) / Drug target genes : 49 - Drug target pathways : 109

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02661711
(ClinicalTrials.gov)
March 201613/1/2016Aflibercept for Macular Oedema With Underlying Retinitis Pigmentosa (AMOUR) StudyProspective Non-randomised Exploratory Study to Assess the Safety and Efficacy of Aflibercept (Eylea) in Cystoid Macular Oedema (CMO) Associated With Retinitis Pigmentosa (RP)Macular Oedema;Retinitis PigmentosaDrug: AfliberceptMoorfields Eye Hospital NHS Foundation TrustBayerActive, not recruiting16 YearsN/ABoth30Phase 2United Kingdom
2EUCTR2015-003723-65-GB
(EUCTR)
12/01/201606/01/2016Prospective non-randomised pilot study looking at the safety and efficacy of a drug called Eylea for patients with an eye condition called Retinitis Pigmentosa, that also have swelling at the back of the eyeAflibercept (Eylea®) for macular oedema associated with underlying Retinitis Pigmentosa (AMOUR) - AMOUR Retinitis Pigmentosa associated Cystoid Macular Oedema
MedDRA version: 18.1;Level: PT;Classification code 10038914;Term: Retinitis pigmentosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Eye Diseases [C11]
Trade Name: Eylea
Product Name: Eylea
Product Code: n/a
INN or Proposed INN: Aflibercept
Moorfields Eye HospitalNULLNot Recruiting Female: yes
Male: yes
30 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noUnited Kingdom